Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Multiple Sclerosis

Free Subscription 23.02.2026 1 AJNR Am J Neuroradiol 1 BMC Neurol 1 J Neurol 3 Mult Scler 1 Neurol Clin Pract 1 Neurology 2 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJNR Am J Neuroradiol

1. PETROU K, Ploussi A, Seimenis I, Karavasilis E, et al
   Radiomics and Artificial Intelligence in Multiple Sclerosis MRI: A Comprehensive Review.
   AJNR Am J Neuroradiol. 2026 Feb 19:ajnr.A9245. doi: 10.3174/ajnr.A9245.
   PubMed         Abstract available
   
   

   
   BMC Neurol

2. TAN H, Zhou L, Gao Y, Zhao C, et al
   Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China.
   BMC Neurol. 2026 Feb 18. doi: 10.1186/s12883-026-04727.
   PubMed         Abstract available
   
   

   
   J Neurol

3. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
   Disability progression in multiple sclerosis: a latent class analysis of predictors.
   J Neurol. 2026;273:157.
   PubMed         Abstract available
   
   

   
   Mult Scler

4. SIAVOSHI F, Noroozi R, Chang G, Schoeps VA, et al
   Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis.
   Mult Scler. 2026 Feb 20:13524585261417120. doi: 10.1177/13524585261417120.
   PubMed         Abstract available
   
   
5. MILLER A, Cohen JA, Karni A, Popper L, et al
   GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.
   Mult Scler. 2026;32:202-213.
   PubMed         Abstract available
   
   
6. PATEL MA, Punnen TG, Shan KS, McCreary MC, et al
   Clinical and radiological outcomes of directed treatment transitions from Gilenya((R)) to generic fingolimod.
   Mult Scler. 2026;32:192-201.
   PubMed         Abstract available
   
   

   
   Neurol Clin Pract

7. HARTUNG DM, Gabriel N, Gellad WF, Cameron T, et al
   Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021.
   Neurol Clin Pract. 2026;16:e200597.
   PubMed         Abstract available
   
   

   
   Neurology

8. CHANDRA A, Acharya S, Chandra A
   Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal: Overcoming Barriers Through Local Adaptations.
   Neurology. 2026;106:e214743.
   PubMed         Abstract available
   
   

   
   PLoS One

9. DENG Q, Bai Q, Yang Y, Tang W, et al
   A new mechanism regulating microglial NLRP3 inflammasome: FMR1 mediates NLRP3 mRNA stability.
   PLoS One. 2026;21:e0341867.
   PubMed         Abstract available
   
   
10. AKBARI H, Ragerdi-Kashani I, Rezaei-Yazdi F, Pasbakhsh P, et al
    Effect of transplanted oligodendrocyte precursor cells derived from inflammatory and non-inflammatory microenvironment on remyelination in a chronic cuprizone model.
    PLoS One. 2026;21:e0343039.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

11. SARRAZIN N, Arab R, Cordano C, Brazhnikova E, et al
    Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination.
    Proc Natl Acad Sci U S A. 2026;123:e2520161123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum